A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.
The latest deal over a CD47 asset has got investors wondering who could be next.
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
Sanofi’s $3.2bn move for Translate Bio leaves Arcturus as one of the few affordable independent mRNA players.
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
The deal puts more support behind targeting folate receptor α, a long troubled target, with antibody-drug conjugates.
But this week three transactions did squeak through.